en
/
sv
About Elicera
Elicera in brief
Board
Management
Elicera's history
Immuno-oncology
What is immuno-oncology?
Oncolytic virus
CAR T-cell therapy
Technology
Strengths
iTANK-platform
ELC-100
ELC-201
ELC-301
ELC-401
Patents
Pipeline
Pipeline
Clinical trials
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
IPO
News
News
Press Releases
Events
Contact
en
/
sv
Press Releases
2021
2020
All
Regulatory
Jul 5, 2021
Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market
Regulatory
Read more
Jul 5, 2021
Elicera Therapeutics' board and management buy shares
Regulatory
Read more
Jun 24, 2021
Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus
Regulatory
Read more
Jun 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory
Read more
Jun 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory
Read more
Jun 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory
Read more
Apr 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory
Read more
Apr 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory
Read more
Mar 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory
Read more
Jan 11, 2021
Elicera Therapeutics recruits CFO
Regulatory
Read more
Jan 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory
Read more
Oct 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory
Read more
Apr 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory
Read more
No regulatory Press Releases
All
Regulatory
Jul 5, 2021
Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market
Regulatory
Read more
Jul 5, 2021
Elicera Therapeutics' board and management buy shares
Regulatory
Read more
Jun 24, 2021
Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus
Regulatory
Read more
Jun 10, 2021
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Regulatory
Read more
Jun 9, 2021
Elicera Therapeutics' new issue heavily oversubscribed
Regulatory
Read more
Jun 4, 2021
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory
Read more
May 24, 2021
Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market
Regulatory
Read more
Apr 27, 2021
Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses
Regulatory
Read more
Apr 15, 2021
Biostock writes about Elicera and CAR T-cells
Regulatory
Read more
Mar 22, 2021
Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board
Regulatory
Read more
Jan 11, 2021
Elicera Therapeutics recruits CFO
Regulatory
Read more
Jan 8, 2021
Elicera Therapeutics invitation to company presentation (in Swedish)
Regulatory
Read more
Oct 5, 2020
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
Regulatory
Read more
Apr 23, 2020
Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100
Regulatory
Read more
No regulatory Press Releases
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept
